Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy (Tivicay) Versus the Maintenance of a Successful Triple Therapy Using Abacavir + Lamivudine + Dolutegravir (Triumeq) in HIV-1- Infected Patients
Phase of Trial: Phase III
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Dolutegravir (Primary) ; Abacavir/dolutegravir/lamivudine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms MONCAY
- 07 Jun 2017 Biomarkers information updated
- 24 Mar 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2018.
- 20 Jan 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.